VCNX vaccinex.com: Enterprise Value to EBITDA Ratio

Graphic logo of Vaccinex (VCNX)

Vaccinex, Inc. (VCNX) develops antibodies to combat oncology and neuronal degeneration, utilizing proprietary platforms to ensure long-term project cycles. This chart on GURU.Markets for the EV/EBITDA metric shows . Company management strictly controls expenses, seeking new funding sources due to liquidity shortage risks. Additionally, the business is developing partnerships with clinics to test drugs for Huntington's and Alzheimer's diseases.

Vaccinex, Inc - VCNX Total Company Value to Operating Income Before Depreciation Ratio (period 07/04/2022 - 11/12/2026)

Summary analytical data breakdowns for vaccinex.com (VCNX)

- stock price and consensus target price:
Stock Quotes Vaccinex, Inc|VCNX - Average Forecast Price
- company stock capitalization data:
Market Valuation Vaccinex Inc|VCNX - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Vaccinex|VCNX - Book Valuation of Business|Market Value to Book Value Ratio vaccinex.com|VCNX - Cumulative Company Assets
- debt and solvency information:
Debt to Equity Vaccinex, Inc.|VCNX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Vaccinex|VCNX - Company Aggregate Debts|Debt to Book Capitalization Ratio Vaccinex Inc|VCNX - Company Long-Term Indebtedness|Company Short-Term Debt Vaccinex|Quick Liquidity Indicator vaccinex.com
- financial results and valuation multiples details:
VCNX - Annual Net Income|Future Profit Vaccinex, Inc.|VCNX - Market Price to Net Income Ratio|Forward P/E Multiple Vaccinex, Inc.|VCNX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Vaccinex Inc|VCNX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Vaccinex|VCNX - Earnings per share for the trailing year|Quarterly EPS earnings growth vaccinex.com|VCNX - Earnings growth in current year|Net earnings per share growth forecast for next year Vaccinex, Inc.
Fundamental company analysis:VCNX (Vaccinex, Inc)
Original product of Vaccinex Inc.

Investors in Vaccinex, Inc. (VCNX) face a choice between growth potential and debt risks amid inflationary pressures. The EV/EBITDA ratio trajectory reflects the relationship between total enterprise value and operating profit, allowing for an assessment of the real value of assets net of debt. This metric is critical, as the robotization of tissue analysis in oncology requires significant capital expenditures in intelligent systems.

Competitor analysis for Vaccinex, Inc.

ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Immatics Biotechnologies (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|Enterprise Value to EBITDA Ratio compasstherapeutics.com CMPX|Replimune - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology, Inc.) - Enterprise Value to Operating Income Before Depreciation|cgen.com (CGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA iobiotech.com (IOBT)|Enterprise Value to EBITDA Ratio STRO|INKT - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio HOWL (Werewolf Therapeutics)|Enterprise Value to Operating Income Before Depreciation Ratio IMMX|EV/EBITDA Multiple ALXO (ALX Oncology)|Business Value to Operating Income Before Depreciation CUE|PDS Biotechnology Corp - EV/EBITDA Multiple|Company Value to EBITDA Sonnet BioTherapeutics|MAIA Biotechnology Inc (MAIA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Liminatus - Business Value to Operating Income Before Depreciation|LVTX (LAVA Therapeutics NV) - EV/EBITDA Multiple|EV/EBITDA Multiple nextcure.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Leap Therapeutics, Inc. (LPTX)|INTS: Company Value to Operating Income Before Depreciation Ratio|Sensei Biotherapeutics, Inc. - Enterprise Value to EBITDA Ratio|Theriva Corp (TOVX) - Company Value to EBITDA|GRTS: Enterprise Value to EBITDA Ratio|KA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NEXI: EV/EBITDA Multiple|Turnstone Biologics Corp. (TSBX) - EV/EBITDA Multiple|HARP (Harpoon Tx) - EV/EBITDA Multiple